Tonix Pharmaceuticals (NASDAQ: TNXP), a fully integrated, commercial-stage biotechnology company, will host a conference call and webcast on Monday, Nov. 9, 2026, at 8:30 a.m. ET to report its third-quarter 2026 financial results and operational highlights.
The timing of the announcement is significant for investors and patients alike. Tonix is at a pivotal stage: it is commercializing TONMYA(TM) (cyclobenzaprine HCl sublingual tablets 2.8mg), which the company describes as the first new treatment for fibromyalgia in more than 15 years. The quarterly update will be the first since the company began marketing that flagship medicine, and it will offer Wall Street its clearest view yet of how quickly the product is reaching patients and generating revenue.
Tonix’s CNS commercial infrastructure also supports its marketed acute migraine products, Zembrace(R) SymTouch(R) and Tosymra(R), giving the company multiple revenue streams in neurology. Beyond the commercial portfolio, Tonix is maximizing the science behind TONMYA in Phase 2 clinical trials to evaluate its potential in major depressive disorder and acute stress disorder. Those studies could eventually expand the drug’s label well beyond fibromyalgia, a possibility that carries substantial long-term value if the data hold up.
The company’s pipeline extends further. Its CNS portfolio includes TNX-2900, which is Phase 2 ready for the treatment of Prader-Willi syndrome, a rare disease. Tonix is also advancing immunology programs, including monoclonal antibody TNX-4800 for Lyme disease prophylaxis and TNX-1500, a third-generation CD40 ligand inhibitor for the prevention of kidney transplant rejection. Tonix cautions that its product development candidates are investigational new drugs or biologics and that their efficacy and safety have not been established and they have not been approved for any indication.
Investors and interested parties can register to participate in the conference call or view the webcast through the company. A replay will be available under “IR Events” in the Investors section of the Tonix website. The full press release is available at https://nnw.fm/va44Q, and the latest news and updates relating to TNXP are available in the company’s newsroom at https://nnw.fm/TNXP.
The announcement was distributed through NetworkNewsWire, a specialized communications platform focused on financial news and content distribution for private and public companies and the investment community. NNW is one of 75+ brands within the Dynamic Brand Portfolio at IBN, which provides access to wire solutions via InvestorWire, editorial syndication to 5,000+ outlets, press release enhancement, social media distribution, and tailored corporate communications solutions. Terms of use and disclaimers applicable to all content provided by NNW are available at https://www.NetworkNewsWire.com/Disclaimer.
